<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802890</url>
  </required_header>
  <id_info>
    <org_study_id>QIB01/2018</org_study_id>
    <nct_id>NCT03802890</nct_id>
  </id_info>
  <brief_title>Microbial Dysbiosis in Rheumatoid Arthritis</brief_title>
  <acronym>MyRA</acronym>
  <official_title>Microbial Dysbiosis in the Pathogenesis of Rheumatoid Arthritis: Using Metagenomics to Predict Methotrexate Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quadram Institute Bioscience</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Action Arthritis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of East Anglia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norfolk and Norwich University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Quadram Institute Bioscience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MyRA study will primarily investigate whether there are associations between the&#xD;
      structure and function of the gut microbiome and response to methotrexate in early rheumatoid&#xD;
      arthritis patients. The microbiome will be characterised via shotgun metagenomic sequencing&#xD;
      of microbial DNA present in stool samples taken during the participant's first 6 months of&#xD;
      taking methotrexate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methotrexate is often the first drug of choice for patients with early rheumatoid arthritis&#xD;
      (RA), but its efficacy is highly variable and it can lead to severe side effects. There are&#xD;
      currently no reliable predictors of methotrexate efficacy for people with early RA.&#xD;
&#xD;
      Microbial dysbiosis (an imbalanced microbiome) has recently been implicated in RA, with&#xD;
      associations between specific microbes and RA biomarkers or disease activity. Gut microbes&#xD;
      have extensive capabilities in terms of xenobiotic (e.g. drug) metabolism. Several gut&#xD;
      microbes are able to alter the drug methotrexate in vitro, and it is possible this could&#xD;
      effect drug efficacy in vivo. Alternatively methotrexate efficacy could be affected by&#xD;
      baseline microbial composition or alterations to microbial composition over the course of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in DAS28-CRP score</measure>
    <time_frame>0-6 months</time_frame>
    <description>Disease Activity Score using 28 joints and C-reactive Protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SDAI score</measure>
    <time_frame>0-6 months</time_frame>
    <description>Simplified Disease Activity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of CRP in blood</measure>
    <time_frame>0-6 months</time_frame>
    <description>C-reactive Protein (an inflammatory biomarker)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESR value (blood)</measure>
    <time_frame>0-6 months</time_frame>
    <description>Erythrocyte Sedimentation Rate (an inflammatory biomarker)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of anti-CCP in blood</measure>
    <time_frame>0-6 months</time_frame>
    <description>Anti-Cyclic Citrullinated peptide (disease-specific antibody)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of RF in blood</measure>
    <time_frame>0-6 months</time_frame>
    <description>Rheumatoid Factor (disease-specific antibody)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  faecal samples&#xD;
&#xD;
        -  blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Early rheumatoid arthritis commencing methotrexate monotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years of age&#xD;
&#xD;
          -  RA diagnosis based on ACR 2010 classification criteria with symptoms starting within&#xD;
             the last 2 years&#xD;
&#xD;
          -  Referred by GP to the Early Arthritis Clinic at the Norfolk and Norwich University&#xD;
             Hospitals NHS trust&#xD;
&#xD;
          -  Commencing methotrexate monotherapy for the first time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Initially commencing combination therapy (prior to first stool sample) rather than&#xD;
             methotrexate monotherapy i.e. MTX combined with another DMARD or prednisolone&#xD;
&#xD;
          -  Commencement of MTX therapy prior to first stool sample or cessation of MTX therapy at&#xD;
             any point during the study&#xD;
&#xD;
          -  History of psoriasis&#xD;
&#xD;
          -  Those currently suffering from, or have ever suffered from, any diagnosed&#xD;
             gastrointestinal disease, gastrointestinal disorders including regular diarrhoea and&#xD;
             constipation (excluding hiatus hernia unless symptomatic) and/or have undergone&#xD;
             gastrointestinal surgery.&#xD;
&#xD;
          -  Those regularly (3+ times/week) taking self-prescribed over the counter medications&#xD;
             for digestive/gastrointestinal conditions&#xD;
&#xD;
          -  Use of laxatives within 7 days prior to sampling unless these have been used on a&#xD;
             regular basis (3+ times/week) for more than one month prior to the study and will&#xD;
             continue to be used throughout the study period&#xD;
&#xD;
          -  The use of over-the-counter medications or food/drinks containing pre and/or&#xD;
             probiotics within 7 days prior to sampling, unless these have been used on a regular&#xD;
             basis (3+ times/week) for more than one month prior to the study and will continue to&#xD;
             be used throughout the study period&#xD;
&#xD;
          -  Significant alteration of the participant's normal diet at any point during the study&#xD;
             (e.g. adoption of the 5:2 fasting diet)&#xD;
&#xD;
          -  Regular (3+ times/week) or recent (within 3 months) use of colonic irrigation or other&#xD;
             bowel cleansing techniques&#xD;
&#xD;
          -  Recently returned to the UK following a period abroad, and who have suffered gastric&#xD;
             symptoms during the period abroad or on return to the UK. These will be assessed on an&#xD;
             individual basis&#xD;
&#xD;
          -  Currently taking or finished a course of antibiotics within the last 3 months&#xD;
&#xD;
          -  Currently pregnant or lactating&#xD;
&#xD;
          -  Living with or related to any member of the Study Team&#xD;
&#xD;
          -  Those who have limited or no understanding of spoken and written English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Carding, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Quadram Institute Bioscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbial dysbiosis</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>dietary factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03802890/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

